| 1 | cost-effectiveness | 7,016 |
| 2 | risk-benefit | 445 |
| 3 | cost-utility | 415 |
| 4 | cost-benefit | 324 |
| 5 | possession | 226 |
| 6 | risk/benefit | 207 |
| 7 | benefit-risk | 188 |
| 8 | benefit/risk | 133 |
| 9 | efficacy/safety | 68 |
| 10 | cost-efficacy | 60 |
| 11 | benefit-to-risk | 54 |
| 12 | cost/benefit | 34 |
| 13 | risk-to-benefit | 34 |
| 14 | cost/qaly | 28 |
| 15 | cost-of-illness | 17 |
| 16 | harm-benefit | 16 |
| 17 | net-benefit | 15 |
| 18 | efficacy/tolerability | 14 |
| 19 | efficacy/toxicity | 14 |
| 20 | o-demethylation | 14 |
| 21 | benefit-harm | 13 |
| 22 | 15:2 | 12 |
| 23 | cost-effect | 12 |
| 24 | tumor-to-background | 12 |
| 25 | powder/liquid | 10 |
| 26 | benefit-to-harm | 9 |
| 27 | bioavailability/bioequivalence | 9 |
| 28 | roc-curve | 9 |
| 29 | a/h | 8 |
| 30 | cost-per-qaly | 8 |
| 31 | costeffectiveness | 8 |
| 32 | heterogeneity-adjusted | 8 |
| 33 | ldl/hdl-cholesterol | 8 |
| 34 | return-on-investment | 8 |
| 35 | cost/effectiveness | 7 |
| 36 | gain-to-feed | 7 |
| 37 | a/t-ghr | 6 |
| 38 | er/ir | 6 |
| 39 | liquid/solid | 6 |
| 40 | remanence | 6 |
| 41 | rpav/mpav | 6 |
| 42 | brain/plasma | 5 |
| 43 | cholesterol-lipoproteins | 5 |
| 44 | olinia | 5 |
| 45 | qt/qs2 | 5 |
| 46 | risk/benefits | 5 |
| 47 | tryptophan/lnaa | 5 |
| 48 | collocation | 4 |
| 49 | metastasis-to-liver | 4 |
| 50 | rorc/foxp3 | 4 |
| 51 | roughage-to-concentrate | 4 |
| 52 | sbp/lvids | 4 |
| 53 | signal-noise | 4 |
| 54 | 16:1/16:0 | 3 |
| 55 | abdominal/hip | 3 |
| 56 | apob/a-i | 3 |
| 57 | apob/apoai | 3 |
| 58 | bax/bcl-xl | 3 |
| 59 | c-value | 3 |
| 60 | choline/n-acetylaspartate | 3 |
| 61 | cost-to-benefit | 3 |
| 62 | cost/effect | 3 |
| 63 | diagnosticity | 3 |
| 64 | dome-to-neck | 3 |
| 65 | dose-potency | 3 |
| 66 | ess/lvids | 3 |
| 67 | flexion-relaxation | 3 |
| 68 | hdlc/ldlc | 3 |
| 69 | mda/mdma | 3 |
| 70 | mmp-8/timp-1 | 3 |
| 71 | qao/kelv | 3 |
| 72 | serotonin/tryptophan | 3 |
| 73 | systole/diastole | 3 |
| 74 | tat/d-dimer | 3 |
| 75 | tbx21/gata3 | 3 |
| 76 | timp-3/mmp-9 | 3 |
| 77 | tumor-to-nontumor | 3 |
| 78 | vegf/tsp-1 | 3 |
| 79 | zno/b2o3 | 3 |
| 80 | aldosterone/pra | 2 |
| 81 | apizym | 2 |
| 82 | auc24/mpc | 2 |
| 83 | benefit/cost | 2 |
| 84 | bifidobacterium/escherichia | 2 |
| 85 | c3/dose | 2 |
| 86 | ca/c | 2 |
| 87 | cacg/cb | 2 |
| 88 | cd4/cd3 | 2 |
| 89 | cis/trans-flavan-3-ol | 2 |
| 90 | column-to-column | 2 |
| 91 | costs/qaly | 2 |
| 92 | decidua/placenta | 2 |
| 93 | dheas-to-c | 2 |
| 94 | dose-benefit | 2 |
| 95 | e/e'av | 2 |
| 96 | em/amrv | 2 |
| 97 | hdl-2/hdl-3 | 2 |
| 98 | hs/cs | 2 |
| 99 | ifngamma/il-4 | 2 |
| 100 | il-1ra/il-1β | 2 |
| 101 | il-5/ifn-gamma | 2 |
| 102 | k/f | 2 |
| 103 | l-tryptophan/caa | 2 |
| 104 | lathosterol-cholesterol | 2 |
| 105 | ldbp | 2 |
| 106 | level-to-dose | 2 |
| 107 | medico-economical | 2 |
| 108 | meta-odds | 2 |
| 109 | mufa/sfa | 2 |
| 110 | myoinositol/creatine | 2 |
| 111 | noise-to-harmonics | 2 |
| 112 | off-gas | 2 |
| 113 | oor | 2 |
| 114 | os-hazard | 2 |
| 115 | ox-ldl/hdl-c | 2 |
| 116 | p/t-gsk-3β | 2 |
| 117 | pdc/mdc | 2 |
| 118 | pharmaco-toxicological | 2 |
| 119 | phospho/total | 2 |
| 120 | ptau181-aβ42 | 2 |
| 121 | quartile-based | 2 |
| 122 | rc/mpc | 2 |
| 123 | risk-effect | 2 |
| 124 | rv-free-str-e/a | 2 |
| 125 | safety-efficacy | 2 |
| 126 | screening/enrollment | 2 |
| 127 | solid-to-liquid | 2 |
| 128 | tetrahydrocorticosterone/allotetrahydrocorticosterone | 2 |
| 129 | toeprinting | 2 |
| 130 | tot-c/hdl-c | 2 |
| 131 | tryptophan/caa | 2 |
| 132 | tumor/blood | 2 |
| 133 | tumor/muscle | 2 |
| 134 | tyrosine/caa | 2 |
| 135 | u-prot/u-cr | 2 |
| 136 | villus-to-crypt | 2 |
| 137 | villus/crypt | 2 |
| 138 | vldl-c/vldl-tg | 2 |
| 139 | water-to-powder | 2 |
| 140 | wpi-to-ga | 2 |
| 141 | β-sitosterol/cholesterol | 2 |
| 142 | 14:1:6:8 | 1 |
| 143 | 3:2:16 | 1 |
| 144 | 5-hiaa:5-ht | 1 |
| 145 | a/amv | 1 |
| 146 | activity/acceptability | 1 |
| 147 | acyl-/des-acyl-ghrelin | 1 |
| 148 | adp/o | 1 |
| 149 | alpha-tocopherol-to-cholesterol | 1 |
| 150 | alveolar/artery | 1 |
| 151 | analysis/decision | 1 |
| 152 | androstenedione/cortisol | 1 |
| 153 | ang2/ang1 | 1 |
| 154 | apob-apoa-1 | 1 |
| 155 | apob-apoa1 | 1 |
| 156 | ara/epa | 1 |
| 157 | attack/skipping | 1 |
| 158 | band-neutrophil | 1 |
| 159 | benefit/damage | 1 |
| 160 | benefits-to-harms | 1 |
| 161 | blastocyst/oocyte | 1 |
| 162 | bolus/demand | 1 |
| 163 | bup/nbup | 1 |
| 164 | capillary-to-myocyte | 1 |
| 165 | cbn/thc | 1 |
| 166 | class-risk | 1 |
| 167 | compliance.mixed | 1 |
| 168 | concentration/molar | 1 |
| 169 | cortisol-to-copeptin | 1 |
| 170 | cost/qol | 1 |
| 171 | costs/benefits | 1 |
| 172 | crown-to-implant | 1 |
| 173 | cup-disk | 1 |
| 174 | cup/disk | 1 |
| 175 | de/dcp | 1 |
| 176 | deltaet/deltano | 1 |
| 177 | drug-beeswax | 1 |
| 178 | e't/a't | 1 |
| 179 | e/e1 | 1 |
| 180 | e/tvi | 1 |
| 181 | efficacy-to-tolerability | 1 |
| 182 | efficacy-to-toxicity | 1 |
| 183 | efficacy/acceptability | 1 |
| 184 | efficiency/tolerance | 1 |
| 185 | electricity-selling | 1 |
| 186 | elemental-abundance | 1 |
| 187 | em-to-am | 1 |
| 188 | fe/cd | 1 |
| 189 | fe3o4/koh+glucose | 1 |
| 190 | fetus/placenta | 1 |
| 191 | four-atom | 1 |
| 192 | ghrelin/obestatin | 1 |
| 193 | gmc/gmt | 1 |
| 194 | harmonic-to-noise | 1 |
| 195 | hdl-2-c/hdl-c | 1 |
| 196 | hdl-c/cholesterol | 1 |
| 197 | hdl-cholesterol/ldl-cholesterol | 1 |
| 198 | hepcidin/ferritin | 1 |
| 199 | hmw/total | 1 |
| 200 | iga/c3 | 1 |
| 201 | igf-i/igfbp3 | 1 |
| 202 | igg4/igg | 1 |
| 203 | il-12p70/il-12p40 | 1 |
| 204 | il-17/tgf-β | 1 |
| 205 | ima/albumin | 1 |
| 206 | initial-waist/height | 1 |
| 207 | interleukin-6/interleukin-10 | 1 |
| 208 | intima-to-media | 1 |
| 209 | kleiber | 1 |
| 210 | lc3bii/i | 1 |
| 211 | ld5/ic50 | 1 |
| 212 | ldl-chol-to-hdl-chol | 1 |
| 213 | ldl/apob | 1 |
| 214 | long-axis/length-area | 1 |
| 215 | low-to-high-frequency | 1 |
| 216 | lung-weight-to-body-weight | 1 |
| 217 | m-tyrosine/phenylalanine | 1 |
| 218 | magnesium/potassium | 1 |
| 219 | me-to-gain | 1 |
| 220 | member-provider | 1 |
| 221 | methanol/oil | 1 |
| 222 | msv/esv | 1 |
| 223 | nadh/nad+ | 1 |
| 224 | nitrogen-isotope | 1 |
| 225 | no/et-1 | 1 |
| 226 | norepinephrine/cortisol | 1 |
| 227 | obestatin-to-ghrelin | 1 |
| 228 | obestatin/ghrelin | 1 |
| 229 | omega-3/-6 | 1 |
| 230 | p-erk/erk | 1 |
| 231 | pat/ch | 1 |
| 232 | pc/lpc | 1 |
| 233 | pdvhp/thp | 1 |
| 234 | pep-to-lvet | 1 |
| 235 | proinsulin-to-adiponectin | 1 |
| 236 | promoter/inhibitor | 1 |
| 237 | protein/rna | 1 |
| 238 | proteinuria-creatinine | 1 |
| 239 | pwrmax/edvbeta | 1 |
| 240 | reqrr/arr | 1 |
| 241 | rlp-c/tg | 1 |
| 242 | signal-versus-noise | 1 |
| 243 | smr/beta2 | 1 |
| 244 | solvent-to-solid | 1 |
| 245 | sound-to-noise | 1 |
| 246 | subscapula-to-triceps | 1 |
| 247 | substrate/cell | 1 |
| 248 | t4s/t4 | 1 |
| 249 | tapse-to-pasp | 1 |
| 250 | tau/aβ42 | 1 |
| 251 | thetcd4/tcd8 | 1 |
| 252 | thigh-to-abdomen | 1 |
| 253 | tnf-alpha/il-10 | 1 |
| 254 | torque-emg | 1 |
| 255 | transition/transversion | 1 |
| 256 | tumor-to-brain | 1 |
| 257 | tumor-to-nontarget-organs | 1 |
| 258 | tumour/stroma | 1 |
| 259 | txb2/pgf1alpha | 1 |
| 260 | tyrosine/lnaa | 1 |
| 261 | vegf-c/svegfr-3 | 1 |
| 262 | ventriculocranial | 1 |
| 263 | vessel-to-volume | 1 |
| 264 | waist-hit | 1 |
| 265 | wc/hip | 1 |
| 266 | weight-head | 1 |
| 267 | width-to-length | 1 |
| 268 | β/α-mhc | 1 |
| 1 | 14:1:6:8 | 1 |
| 2 | 15:2 | 12 |
| 3 | 16:1/16:0 | 3 |
| 4 | 3:2:16 | 1 |
| 5 | 5-hiaa:5-ht | 1 |
| 6 | a/amv | 1 |
| 7 | a/h | 8 |
| 8 | a/t-ghr | 6 |
| 9 | abdominal/hip | 3 |
| 10 | activity/acceptability | 1 |
| 11 | acyl-/des-acyl-ghrelin | 1 |
| 12 | adp/o | 1 |
| 13 | aldosterone/pra | 2 |
| 14 | alpha-tocopherol-to-cholesterol | 1 |
| 15 | alveolar/artery | 1 |
| 16 | analysis/decision | 1 |
| 17 | androstenedione/cortisol | 1 |
| 18 | ang2/ang1 | 1 |
| 19 | apizym | 2 |
| 20 | apob-apoa-1 | 1 |
| 21 | apob-apoa1 | 1 |
| 22 | apob/a-i | 3 |
| 23 | apob/apoai | 3 |
| 24 | ara/epa | 1 |
| 25 | attack/skipping | 1 |
| 26 | auc24/mpc | 2 |
| 27 | band-neutrophil | 1 |
| 28 | bax/bcl-xl | 3 |
| 29 | benefit-harm | 13 |
| 30 | benefit-risk | 188 |
| 31 | benefit-to-harm | 9 |
| 32 | benefit-to-risk | 54 |
| 33 | benefit/cost | 2 |
| 34 | benefit/damage | 1 |
| 35 | benefit/risk | 133 |
| 36 | benefits-to-harms | 1 |
| 37 | bifidobacterium/escherichia | 2 |
| 38 | bioavailability/bioequivalence | 9 |
| 39 | blastocyst/oocyte | 1 |
| 40 | bolus/demand | 1 |
| 41 | brain/plasma | 5 |
| 42 | bup/nbup | 1 |
| 43 | c-value | 3 |
| 44 | c3/dose | 2 |
| 45 | ca/c | 2 |
| 46 | cacg/cb | 2 |
| 47 | capillary-to-myocyte | 1 |
| 48 | cbn/thc | 1 |
| 49 | cd4/cd3 | 2 |
| 50 | cholesterol-lipoproteins | 5 |
| 51 | choline/n-acetylaspartate | 3 |
| 52 | cis/trans-flavan-3-ol | 2 |
| 53 | class-risk | 1 |
| 54 | collocation | 4 |
| 55 | column-to-column | 2 |
| 56 | compliance.mixed | 1 |
| 57 | concentration/molar | 1 |
| 58 | cortisol-to-copeptin | 1 |
| 59 | cost-benefit | 324 |
| 60 | cost-effect | 12 |
| 61 | cost-effectiveness | 7,016 |
| 62 | cost-efficacy | 60 |
| 63 | cost-of-illness | 17 |
| 64 | cost-per-qaly | 8 |
| 65 | cost-to-benefit | 3 |
| 66 | cost-utility | 415 |
| 67 | cost/benefit | 34 |
| 68 | cost/effect | 3 |
| 69 | cost/effectiveness | 7 |
| 70 | cost/qaly | 28 |
| 71 | cost/qol | 1 |
| 72 | costeffectiveness | 8 |
| 73 | costs/benefits | 1 |
| 74 | costs/qaly | 2 |
| 75 | crown-to-implant | 1 |
| 76 | cup-disk | 1 |
| 77 | cup/disk | 1 |
| 78 | de/dcp | 1 |
| 79 | decidua/placenta | 2 |
| 80 | deltaet/deltano | 1 |
| 81 | dheas-to-c | 2 |
| 82 | diagnosticity | 3 |
| 83 | dome-to-neck | 3 |
| 84 | dose-benefit | 2 |
| 85 | dose-potency | 3 |
| 86 | drug-beeswax | 1 |
| 87 | e't/a't | 1 |
| 88 | e/e'av | 2 |
| 89 | e/e1 | 1 |
| 90 | e/tvi | 1 |
| 91 | efficacy-to-tolerability | 1 |
| 92 | efficacy-to-toxicity | 1 |
| 93 | efficacy/acceptability | 1 |
| 94 | efficacy/safety | 68 |
| 95 | efficacy/tolerability | 14 |
| 96 | efficacy/toxicity | 14 |
| 97 | efficiency/tolerance | 1 |
| 98 | electricity-selling | 1 |
| 99 | elemental-abundance | 1 |
| 100 | em-to-am | 1 |
| 101 | em/amrv | 2 |
| 102 | er/ir | 6 |
| 103 | ess/lvids | 3 |
| 104 | fe/cd | 1 |
| 105 | fe3o4/koh+glucose | 1 |
| 106 | fetus/placenta | 1 |
| 107 | flexion-relaxation | 3 |
| 108 | four-atom | 1 |
| 109 | gain-to-feed | 7 |
| 110 | ghrelin/obestatin | 1 |
| 111 | gmc/gmt | 1 |
| 112 | harm-benefit | 16 |
| 113 | harmonic-to-noise | 1 |
| 114 | hdl-2-c/hdl-c | 1 |
| 115 | hdl-2/hdl-3 | 2 |
| 116 | hdl-c/cholesterol | 1 |
| 117 | hdl-cholesterol/ldl-cholesterol | 1 |
| 118 | hdlc/ldlc | 3 |
| 119 | hepcidin/ferritin | 1 |
| 120 | heterogeneity-adjusted | 8 |
| 121 | hmw/total | 1 |
| 122 | hs/cs | 2 |
| 123 | ifngamma/il-4 | 2 |
| 124 | iga/c3 | 1 |
| 125 | igf-i/igfbp3 | 1 |
| 126 | igg4/igg | 1 |
| 127 | il-12p70/il-12p40 | 1 |
| 128 | il-17/tgf-β | 1 |
| 129 | il-1ra/il-1β | 2 |
| 130 | il-5/ifn-gamma | 2 |
| 131 | ima/albumin | 1 |
| 132 | initial-waist/height | 1 |
| 133 | interleukin-6/interleukin-10 | 1 |
| 134 | intima-to-media | 1 |
| 135 | k/f | 2 |
| 136 | kleiber | 1 |
| 137 | l-tryptophan/caa | 2 |
| 138 | lathosterol-cholesterol | 2 |
| 139 | lc3bii/i | 1 |
| 140 | ld5/ic50 | 1 |
| 141 | ldbp | 2 |
| 142 | ldl-chol-to-hdl-chol | 1 |
| 143 | ldl/apob | 1 |
| 144 | ldl/hdl-cholesterol | 8 |
| 145 | level-to-dose | 2 |
| 146 | liquid/solid | 6 |
| 147 | long-axis/length-area | 1 |
| 148 | low-to-high-frequency | 1 |
| 149 | lung-weight-to-body-weight | 1 |
| 150 | m-tyrosine/phenylalanine | 1 |
| 151 | magnesium/potassium | 1 |
| 152 | mda/mdma | 3 |
| 153 | me-to-gain | 1 |
| 154 | medico-economical | 2 |
| 155 | member-provider | 1 |
| 156 | meta-odds | 2 |
| 157 | metastasis-to-liver | 4 |
| 158 | methanol/oil | 1 |
| 159 | mmp-8/timp-1 | 3 |
| 160 | msv/esv | 1 |
| 161 | mufa/sfa | 2 |
| 162 | myoinositol/creatine | 2 |
| 163 | nadh/nad+ | 1 |
| 164 | net-benefit | 15 |
| 165 | nitrogen-isotope | 1 |
| 166 | no/et-1 | 1 |
| 167 | noise-to-harmonics | 2 |
| 168 | norepinephrine/cortisol | 1 |
| 169 | o-demethylation | 14 |
| 170 | obestatin-to-ghrelin | 1 |
| 171 | obestatin/ghrelin | 1 |
| 172 | off-gas | 2 |
| 173 | olinia | 5 |
| 174 | omega-3/-6 | 1 |
| 175 | oor | 2 |
| 176 | os-hazard | 2 |
| 177 | ox-ldl/hdl-c | 2 |
| 178 | p-erk/erk | 1 |
| 179 | p/t-gsk-3β | 2 |
| 180 | pat/ch | 1 |
| 181 | pc/lpc | 1 |
| 182 | pdc/mdc | 2 |
| 183 | pdvhp/thp | 1 |
| 184 | pep-to-lvet | 1 |
| 185 | pharmaco-toxicological | 2 |
| 186 | phospho/total | 2 |
| 187 | possession | 226 |
| 188 | powder/liquid | 10 |
| 189 | proinsulin-to-adiponectin | 1 |
| 190 | promoter/inhibitor | 1 |
| 191 | protein/rna | 1 |
| 192 | proteinuria-creatinine | 1 |
| 193 | ptau181-aβ42 | 2 |
| 194 | pwrmax/edvbeta | 1 |
| 195 | qao/kelv | 3 |
| 196 | qt/qs2 | 5 |
| 197 | quartile-based | 2 |
| 198 | rc/mpc | 2 |
| 199 | remanence | 6 |
| 200 | reqrr/arr | 1 |
| 201 | return-on-investment | 8 |
| 202 | risk-benefit | 445 |
| 203 | risk-effect | 2 |
| 204 | risk-to-benefit | 34 |
| 205 | risk/benefit | 207 |
| 206 | risk/benefits | 5 |
| 207 | rlp-c/tg | 1 |
| 208 | roc-curve | 9 |
| 209 | rorc/foxp3 | 4 |
| 210 | roughage-to-concentrate | 4 |
| 211 | rpav/mpav | 6 |
| 212 | rv-free-str-e/a | 2 |
| 213 | safety-efficacy | 2 |
| 214 | sbp/lvids | 4 |
| 215 | screening/enrollment | 2 |
| 216 | serotonin/tryptophan | 3 |
| 217 | signal-noise | 4 |
| 218 | signal-versus-noise | 1 |
| 219 | smr/beta2 | 1 |
| 220 | solid-to-liquid | 2 |
| 221 | solvent-to-solid | 1 |
| 222 | sound-to-noise | 1 |
| 223 | subscapula-to-triceps | 1 |
| 224 | substrate/cell | 1 |
| 225 | systole/diastole | 3 |
| 226 | t4s/t4 | 1 |
| 227 | tapse-to-pasp | 1 |
| 228 | tat/d-dimer | 3 |
| 229 | tau/aβ42 | 1 |
| 230 | tbx21/gata3 | 3 |
| 231 | tetrahydrocorticosterone/allotetrahydrocorticosterone | 2 |
| 232 | thetcd4/tcd8 | 1 |
| 233 | thigh-to-abdomen | 1 |
| 234 | timp-3/mmp-9 | 3 |
| 235 | tnf-alpha/il-10 | 1 |
| 236 | toeprinting | 2 |
| 237 | torque-emg | 1 |
| 238 | tot-c/hdl-c | 2 |
| 239 | transition/transversion | 1 |
| 240 | tryptophan/caa | 2 |
| 241 | tryptophan/lnaa | 5 |
| 242 | tumor-to-background | 12 |
| 243 | tumor-to-brain | 1 |
| 244 | tumor-to-nontarget-organs | 1 |
| 245 | tumor-to-nontumor | 3 |
| 246 | tumor/blood | 2 |
| 247 | tumor/muscle | 2 |
| 248 | tumour/stroma | 1 |
| 249 | txb2/pgf1alpha | 1 |
| 250 | tyrosine/caa | 2 |
| 251 | tyrosine/lnaa | 1 |
| 252 | u-prot/u-cr | 2 |
| 253 | vegf-c/svegfr-3 | 1 |
| 254 | vegf/tsp-1 | 3 |
| 255 | ventriculocranial | 1 |
| 256 | vessel-to-volume | 1 |
| 257 | villus-to-crypt | 2 |
| 258 | villus/crypt | 2 |
| 259 | vldl-c/vldl-tg | 2 |
| 260 | waist-hit | 1 |
| 261 | water-to-powder | 2 |
| 262 | wc/hip | 1 |
| 263 | weight-head | 1 |
| 264 | width-to-length | 1 |
| 265 | wpi-to-ga | 2 |
| 266 | zno/b2o3 | 3 |
| 267 | β-sitosterol/cholesterol | 2 |
| 268 | β/α-mhc | 1 |
| 1 | nadh/nad+ | 1 |
| 2 | tnf-alpha/il-10 | 1 |
| 3 | interleukin-6/interleukin-10 | 1 |
| 4 | il-12p70/il-12p40 | 1 |
| 5 | ld5/ic50 | 1 |
| 6 | 16:1/16:0 | 3 |
| 7 | apob-apoa-1 | 1 |
| 8 | mmp-8/timp-1 | 3 |
| 9 | vegf/tsp-1 | 3 |
| 10 | no/et-1 | 1 |
| 11 | apob-apoa1 | 1 |
| 12 | e/e1 | 1 |
| 13 | ang2/ang1 | 1 |
| 14 | ptau181-aβ42 | 2 |
| 15 | tau/aβ42 | 1 |
| 16 | 15:2 | 12 |
| 17 | smr/beta2 | 1 |
| 18 | qt/qs2 | 5 |
| 19 | hdl-2/hdl-3 | 2 |
| 20 | vegf-c/svegfr-3 | 1 |
| 21 | tbx21/gata3 | 3 |
| 22 | iga/c3 | 1 |
| 23 | cd4/cd3 | 2 |
| 24 | zno/b2o3 | 3 |
| 25 | igf-i/igfbp3 | 1 |
| 26 | rorc/foxp3 | 4 |
| 27 | ifngamma/il-4 | 2 |
| 28 | t4s/t4 | 1 |
| 29 | omega-3/-6 | 1 |
| 30 | 3:2:16 | 1 |
| 31 | 14:1:6:8 | 1 |
| 32 | thetcd4/tcd8 | 1 |
| 33 | timp-3/mmp-9 | 3 |
| 34 | rv-free-str-e/a | 2 |
| 35 | tyrosine/caa | 2 |
| 36 | tryptophan/caa | 2 |
| 37 | l-tryptophan/caa | 2 |
| 38 | tyrosine/lnaa | 1 |
| 39 | tryptophan/lnaa | 5 |
| 40 | long-axis/length-area | 1 |
| 41 | mufa/sfa | 2 |
| 42 | wpi-to-ga | 2 |
| 43 | txb2/pgf1alpha | 1 |
| 44 | intima-to-media | 1 |
| 45 | bifidobacterium/escherichia | 2 |
| 46 | olinia | 5 |
| 47 | mda/mdma | 3 |
| 48 | il-5/ifn-gamma | 2 |
| 49 | tumour/stroma | 1 |
| 50 | brain/plasma | 5 |
| 51 | protein/rna | 1 |
| 52 | ara/epa | 1 |
| 53 | aldosterone/pra | 2 |
| 54 | pwrmax/edvbeta | 1 |
| 55 | decidua/placenta | 2 |
| 56 | fetus/placenta | 1 |
| 57 | cacg/cb | 2 |
| 58 | ldl/apob | 1 |
| 59 | hdl-2-c/hdl-c | 1 |
| 60 | tot-c/hdl-c | 2 |
| 61 | ox-ldl/hdl-c | 2 |
| 62 | dheas-to-c | 2 |
| 63 | ca/c | 2 |
| 64 | pdc/mdc | 2 |
| 65 | β/α-mhc | 1 |
| 66 | cbn/thc | 1 |
| 67 | hdlc/ldlc | 3 |
| 68 | pc/lpc | 1 |
| 69 | auc24/mpc | 2 |
| 70 | rc/mpc | 2 |
| 71 | weight-head | 1 |
| 72 | fe/cd | 1 |
| 73 | gain-to-feed | 7 |
| 74 | quartile-based | 2 |
| 75 | heterogeneity-adjusted | 8 |
| 76 | compliance.mixed | 1 |
| 77 | solvent-to-solid | 1 |
| 78 | liquid/solid | 6 |
| 79 | solid-to-liquid | 2 |
| 80 | powder/liquid | 10 |
| 81 | bolus/demand | 1 |
| 82 | tumor-to-background | 12 |
| 83 | tumor/blood | 2 |
| 84 | os-hazard | 2 |
| 85 | elemental-abundance | 1 |
| 86 | efficiency/tolerance | 1 |
| 87 | bioavailability/bioequivalence | 9 |
| 88 | remanence | 6 |
| 89 | benefit/damage | 1 |
| 90 | tumor/muscle | 2 |
| 91 | systole/diastole | 3 |
| 92 | vessel-to-volume | 1 |
| 93 | m-tyrosine/phenylalanine | 1 |
| 94 | proteinuria-creatinine | 1 |
| 95 | myoinositol/creatine | 2 |
| 96 | tetrahydrocorticosterone/allotetrahydrocorticosterone | 2 |
| 97 | nitrogen-isotope | 1 |
| 98 | signal-noise | 4 |
| 99 | harmonic-to-noise | 1 |
| 100 | sound-to-noise | 1 |
| 101 | signal-versus-noise | 1 |
| 102 | fe3o4/koh+glucose | 1 |
| 103 | level-to-dose | 2 |
| 104 | c3/dose | 2 |
| 105 | roughage-to-concentrate | 4 |
| 106 | choline/n-acetylaspartate | 3 |
| 107 | blastocyst/oocyte | 1 |
| 108 | capillary-to-myocyte | 1 |
| 109 | c-value | 3 |
| 110 | roc-curve | 9 |
| 111 | k/f | 2 |
| 112 | igg4/igg | 1 |
| 113 | torque-emg | 1 |
| 114 | electricity-selling | 1 |
| 115 | attack/skipping | 1 |
| 116 | toeprinting | 2 |
| 117 | vldl-c/vldl-tg | 2 |
| 118 | rlp-c/tg | 1 |
| 119 | a/h | 8 |
| 120 | pat/ch | 1 |
| 121 | width-to-length | 1 |
| 122 | apob/a-i | 3 |
| 123 | lc3bii/i | 1 |
| 124 | apob/apoai | 3 |
| 125 | e/tvi | 1 |
| 126 | dome-to-neck | 3 |
| 127 | p-erk/erk | 1 |
| 128 | cup-disk | 1 |
| 129 | cup/disk | 1 |
| 130 | benefit-to-risk | 54 |
| 131 | class-risk | 1 |
| 132 | benefit-risk | 188 |
| 133 | benefit/risk | 133 |
| 134 | pharmaco-toxicological | 2 |
| 135 | medico-economical | 2 |
| 136 | ventriculocranial | 1 |
| 137 | phospho/total | 2 |
| 138 | hmw/total | 1 |
| 139 | band-neutrophil | 1 |
| 140 | methanol/oil | 1 |
| 141 | substrate/cell | 1 |
| 142 | cis/trans-flavan-3-ol | 2 |
| 143 | ldl-chol-to-hdl-chol | 1 |
| 144 | cost/qol | 1 |
| 145 | ldl/hdl-cholesterol | 8 |
| 146 | hdl-cholesterol/ldl-cholesterol | 1 |
| 147 | lathosterol-cholesterol | 2 |
| 148 | alpha-tocopherol-to-cholesterol | 1 |
| 149 | hdl-c/cholesterol | 1 |
| 150 | β-sitosterol/cholesterol | 2 |
| 151 | norepinephrine/cortisol | 1 |
| 152 | androstenedione/cortisol | 1 |
| 153 | bax/bcl-xl | 3 |
| 154 | em-to-am | 1 |
| 155 | four-atom | 1 |
| 156 | benefit-to-harm | 9 |
| 157 | benefit-harm | 13 |
| 158 | magnesium/potassium | 1 |
| 159 | apizym | 2 |
| 160 | serotonin/tryptophan | 3 |
| 161 | thigh-to-abdomen | 1 |
| 162 | me-to-gain | 1 |
| 163 | tumor-to-brain | 1 |
| 164 | acyl-/des-acyl-ghrelin | 1 |
| 165 | obestatin-to-ghrelin | 1 |
| 166 | obestatin/ghrelin | 1 |
| 167 | ima/albumin | 1 |
| 168 | ghrelin/obestatin | 1 |
| 169 | proinsulin-to-adiponectin | 1 |
| 170 | hepcidin/ferritin | 1 |
| 171 | cortisol-to-copeptin | 1 |
| 172 | column-to-column | 2 |
| 173 | analysis/decision | 1 |
| 174 | transition/transversion | 1 |
| 175 | possession | 226 |
| 176 | collocation | 4 |
| 177 | o-demethylation | 14 |
| 178 | flexion-relaxation | 3 |
| 179 | adp/o | 1 |
| 180 | deltaet/deltano | 1 |
| 181 | ldbp | 2 |
| 182 | de/dcp | 1 |
| 183 | pdvhp/thp | 1 |
| 184 | wc/hip | 1 |
| 185 | abdominal/hip | 3 |
| 186 | tapse-to-pasp | 1 |
| 187 | bup/nbup | 1 |
| 188 | concentration/molar | 1 |
| 189 | u-prot/u-cr | 2 |
| 190 | kleiber | 1 |
| 191 | member-provider | 1 |
| 192 | water-to-powder | 2 |
| 193 | tat/d-dimer | 3 |
| 194 | metastasis-to-liver | 4 |
| 195 | a/t-ghr | 6 |
| 196 | er/ir | 6 |
| 197 | tumor-to-nontumor | 3 |
| 198 | oor | 2 |
| 199 | promoter/inhibitor | 1 |
| 200 | reqrr/arr | 1 |
| 201 | off-gas | 2 |
| 202 | hs/cs | 2 |
| 203 | noise-to-harmonics | 2 |
| 204 | meta-odds | 2 |
| 205 | sbp/lvids | 4 |
| 206 | ess/lvids | 3 |
| 207 | benefits-to-harms | 1 |
| 208 | tumor-to-nontarget-organs | 1 |
| 209 | cholesterol-lipoproteins | 5 |
| 210 | subscapula-to-triceps | 1 |
| 211 | cost-effectiveness | 7,016 |
| 212 | cost/effectiveness | 7 |
| 213 | costeffectiveness | 8 |
| 214 | cost-of-illness | 17 |
| 215 | risk/benefits | 5 |
| 216 | costs/benefits | 1 |
| 217 | e't/a't | 1 |
| 218 | risk-effect | 2 |
| 219 | cost-effect | 12 |
| 220 | cost/effect | 3 |
| 221 | pep-to-lvet | 1 |
| 222 | 5-hiaa:5-ht | 1 |
| 223 | initial-waist/height | 1 |
| 224 | lung-weight-to-body-weight | 1 |
| 225 | dose-benefit | 2 |
| 226 | risk-benefit | 445 |
| 227 | harm-benefit | 16 |
| 228 | risk-to-benefit | 34 |
| 229 | cost-to-benefit | 3 |
| 230 | net-benefit | 15 |
| 231 | cost-benefit | 324 |
| 232 | risk/benefit | 207 |
| 233 | cost/benefit | 34 |
| 234 | waist-hit | 1 |
| 235 | gmc/gmt | 1 |
| 236 | crown-to-implant | 1 |
| 237 | screening/enrollment | 2 |
| 238 | return-on-investment | 8 |
| 239 | villus-to-crypt | 2 |
| 240 | villus/crypt | 2 |
| 241 | benefit/cost | 2 |
| 242 | e/e'av | 2 |
| 243 | rpav/mpav | 6 |
| 244 | qao/kelv | 3 |
| 245 | a/amv | 1 |
| 246 | em/amrv | 2 |
| 247 | msv/esv | 1 |
| 248 | drug-beeswax | 1 |
| 249 | cost-efficacy | 60 |
| 250 | safety-efficacy | 2 |
| 251 | dose-potency | 3 |
| 252 | low-to-high-frequency | 1 |
| 253 | cost-per-qaly | 8 |
| 254 | costs/qaly | 2 |
| 255 | cost/qaly | 28 |
| 256 | alveolar/artery | 1 |
| 257 | efficacy/safety | 68 |
| 258 | diagnosticity | 3 |
| 259 | efficacy-to-toxicity | 1 |
| 260 | efficacy/toxicity | 14 |
| 261 | efficacy-to-tolerability | 1 |
| 262 | efficacy/tolerability | 14 |
| 263 | efficacy/acceptability | 1 |
| 264 | activity/acceptability | 1 |
| 265 | cost-utility | 415 |
| 266 | il-17/tgf-β | 1 |
| 267 | il-1ra/il-1β | 2 |
| 268 | p/t-gsk-3β | 2 |